FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes - FDA Press Releases

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

from Food and Drug Administration--Press Releases http://ift.tt/2gQBfnZ
via IFTTT